Verastem, Inc. (VSTM)
Largest Insider Buys in Sector
VSTM Stock Price History Chart
VSTM Stock Performance
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination …
Insider Activity of Verastem, Inc.
Over the last 12 months, insiders at Verastem, Inc. have bought $0 and sold $280,019 worth of Verastem, Inc. stock.
On average, over the past 5 years, insiders at Verastem, Inc. have bought $108,500 and sold $1.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $108,500 was made by BARBERICH TIMOTHY J (director) on 2020‑12‑04.
List of Insider Buy and Sell Transactions, Verastem, Inc.
| 2024-11-05 | Sale | President and CEO | 812 0.002% | $3.84 | $3,118 | -3.49% | ||
| 2024-10-07 | Sale | Chief Financial Officer | 6 <0.0001% | $2.86 | $17 | +25.87% | ||
| 2024-09-24 | Sale | Chief Financial Officer | 28 <0.0001% | $2.68 | $75 | -2.61% | ||
| 2024-09-20 | Sale | Chief Financial Officer | 65 0.0002% | $2.80 | $182 | +8.68% | ||
| 2024-09-19 | Sale | President and CEO | 184 0.0005% | $2.79 | $513 | +8.30% | ||
| 2024-09-19 | Sale | director | 336 0.0008% | $2.79 | $937 | +8.30% | ||
| 2024-09-19 | Sale | director | 131 0.0003% | $2.79 | $365 | +8.30% | ||
| 2024-09-16 | Sale | President and CEO | 246 0.0006% | $2.80 | $689 | +9.89% | ||
| 2024-09-16 | Sale | director | 600 0.0015% | $2.80 | $1,680 | +9.89% | ||
| 2024-09-16 | Sale | director | 287 0.0007% | $2.80 | $804 | +9.89% | ||
| 2024-08-05 | Sale | President and CEO | 3,245 0.0082% | $2.16 | $7,009 | +27.73% | ||
| 2024-07-09 | Sale | Chief Financial Officer | 7 <0.0001% | $2.62 | $18 | 0.00% | ||
| 2024-06-24 | Sale | Chief Financial Officer | 28 0.0001% | $3.15 | $88 | -8.23% | ||
| 2024-06-20 | Sale | President and CEO | 183 0.0007% | $3.21 | $587 | -11.85% | ||
| 2024-06-20 | Sale | director | 335 0.0012% | $3.21 | $1,075 | -11.85% | ||
| 2024-06-20 | Sale | Chief Financial Officer | 67 0.0002% | $3.16 | $212 | -11.85% | ||
| 2024-06-20 | Sale | director | 131 0.0005% | $3.21 | $421 | -11.85% | ||
| 2024-06-17 | Sale | director | 593 0.0024% | $3.49 | $2,070 | -17.15% | ||
| 2024-06-17 | Sale | President and CEO | 244 0.001% | $3.49 | $852 | -17.15% | ||
| 2024-06-17 | Sale | director | 283 0.0011% | $3.49 | $988 | -17.15% |
Insider Historical Profitability
| Paterson Dan | President and CEO | 231576 0.5203% | $3.94 | 5 | 23 | <0.0001% |
| Stuglik Brian M | director | 96109 0.2159% | $3.94 | 1 | 24 | <0.0001% |
| CLARKE JOHN K | director | 2329121 5.2332% | $3.94 | 7 | 0 | +26.77% |
| CHP III LP | 10 percent owner | 2329121 5.2332% | $3.94 | 7 | 0 | +26.77% |
| MPM BIOVENTURES V LLC | 2033333 4.5686% | $3.94 | 1 | 0 |
Institutional Investor Ownership
| Viking Global Investors | $28.98M | 9.7 | 2.46M | 0% | +$0 | 0.01 | |
| Bvf Inc Il | $19.89M | 6.65 | 1.69M | 0% | +$0 | 0.15 | |
| Soleus Capital Management, L.P. | $18.18M | 6.08 | 1.54M | +8.07% | +$1.36M | 0.08 | |
| Vivo Capital | $18.15M | 6.08 | 1.54M | 0% | +$0 | 1.58 | |
| Deerfield Management | $18.15M | 6.08 | 1.54M | 0% | +$0 | 0.04 |